ADHERE: Survey about Pancreatic Cancer Screening Options for People with Inherited Risk

About the Study

The purpose of this study is to understand knowledge and opinions about pancreatic cancer screening, access to and decision-making around screening, and how a blood-based test might influence screening among individuals with inherited (germline) mutations associated with increased pancreatic cancer risk, including APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53. 

We would like to invite you to complete an anonymous survey conducted by FORCE and researchers from Immunovia.  

What the Study Involves

This is a confidential, anonymous online survey that will take about 15 minutes to complete. The survey responses will be used to conduct this study and the data collected for this research may also be used in future research studies. We will not share any personally identifiable information.  

Click here to take the survey in English or Spanish.

Lead Researchers/Study PIs and Affiliation 

Principal Investigator: Norma Alonzo Palma PhD  
Institution: Immunovia   
Contact Email: [email protected]   

People who are 40 years of age or older and who speak either English or Spanish may be eligible if they have an inherited mutation in a gene associated with a higher risk of pancreatic cancer. This includes genes such as APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53. 

People under the age of 40 who do not speak English or Spanish and who do not have an inherited mutation in a gene that is linked to an increased risk of pancreatic cancer.